Tag Archives: reading

#437209 A Renaissance of Genomics and Drugs Is ...

Posted on June 26, 2020 by Android

The causes of aging are extremely complex and unclear. But with longevity clinical trials increasing, more answers—and questions—are emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this article, I’ll explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

Genome Sequencing and Editing
Your genome is the software that runs your body. A sequence of 3.2 billion letters makes you “you.” These base pairs of A’s, T’s, C’s, and G’s determine your hair color, your height, your personality, your propensity for disease, your lifespan, and so on.

Until recently, it’s been very difficult to rapidly and cheaply “read” these letters—and even more difficult to understand what they mean. Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moore’s Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $1,500 in 2015.

Today, the cost of genome sequencing has dropped below $600, and according to Illumina, the world’s leading sequencing company, the process will soon cost about $100 and take about an hour to complete.

This represents one of the most powerful and transformative technology revolutions in healthcare. When we understand your genome, we’ll be able to understand how to optimize “you.”

We’ll know the perfect foods, the perfect drugs, the perfect exercise regimen, and the perfect supplements, just for you.
We’ll understand what microbiome types, or gut flora, are ideal for you (more on this in a later article).
We’ll accurately predict how specific sedatives and medicines will impact you.
We’ll learn which diseases and illnesses you’re most likely to develop and, more importantly, how to best prevent them from developing in the first place (rather than trying to cure them after the fact).

CRISPR Gene Editing
In addition to reading the human genome, scientists can now edit a genome using a naturally occurring biological system discovered in 1987 called CRISPR/Cas9.

Short for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, the editing system was adapted from a naturally-occurring defense system found in bacteria.

Here’s how it works. The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to “remember” the viruses (or closely related ones), and defend against future invasions. If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses’ DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus.

Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods. As a result, CRISPR/Cas9 has swept through labs around the world as the way to edit a genome. A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.

2018: Filled With CRISPR Breakthroughs
Early results are impressive. Researchers have used CRISPR to genetically engineer cocaine resistance into mice, reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs, and reduce genetic deafness in mice.

Already this year, CRISPR-edited immune cells have been shown to successfully kill cancer cells in human patients. Researchers have discovered ways to activate CRISPR with light and use the gene-editing technology to better understand Alzheimer’s disease progression.

With great power comes great responsibility, and the opportunity for moral and ethical dilemmas. In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera. Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.

To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells. Because Jiankui forged ethical review documents and misled doctors in the process, he was sentenced to three years in prison and fined $429,000 last December.

Coupled with significant ethical conversations necessary for progress, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.

Senolytics, Nutraceuticals, and Pharmaceuticals
Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.

What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely. These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse. Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification to localized inflammatory conditions such as osteoarthritis to diminished lung function.

Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.

Prominent companies in the field include the following:

Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology, and pulmonary disease.

Oisin Biotechnologies is pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.

SIWA Therapeutics is working on an immunotherapy approach to the problem of senescent cells.

In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.

(1) Rapamycin

Originally extracted from bacteria found on Easter Island, rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division. Currently, rapamycin derivatives are widely used for immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan and enhanced cognitive and immune function.

PureTech Health subsidiary resTORbio (which went public in 2018) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.

Results of the drug’s recent clinical trial include decreased incidence of infection, improved influenza vaccination response, and a 30.6 percent decrease in respiratory tract infection.

Impressive, to say the least.

(2) Metformin

Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients. Researchers have found that metformin also reduces oxidative stress and inflammation, which otherwise increase as we age. There is strong evidence that metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.

Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of metformin’s protective effect against cancer.

(3) Nutraceuticals and NAD+

Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels.

NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. It’s been shown that NAD+ levels decline as we age.

The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend one’s lifespan. Elysium’s first clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.

Conclusion
These are just a taste of the tremendous momentum that longevity and aging technology has right now. As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.

The next article in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging, and vitality.

We are edging closer toward a dramatically extended healthspan—where 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: Arek Socha from Pixabay Continue reading →

Posted in Human Robots

#437103 How to Make Sense of Uncertainty in a ...

Posted on May 1, 2020 by Android

As the internet churns with information about Covid-19, about the virus that causes the disease, and about what we’re supposed to do to fight it, it can be difficult to see the forest for the trees. What can we realistically expect for the rest of 2020? And how do we even know what’s realistic?

Today, humanity’s primary, ideal goal is to eliminate the virus, SARS-CoV-2, and Covid-19. Our second-choice goal is to control virus transmission. Either way, we have three big aims: to save lives, to return to public life, and to keep the economy functioning.

To hit our second-choice goal—and maybe even our primary goal—countries are pursuing five major public health strategies. Note that many of these advances cross-fertilize: for example, advances in virus testing and antibody testing will drive data-based prevention efforts.

Five major public health strategies are underway to bring Covid-19 under control and to contain the spread of SARS-CoV-2.
These strategies arise from things we can control based on the things that we know at any given moment. But what about the things we can’t control and don’t yet know?

The biology of the virus and how it interacts with our bodies is what it is, so we should seek to understand it as thoroughly as possible. How long any immunity gained from prior infection lasts—and indeed whether people develop meaningful immunity at all after infection—are open questions urgently in need of greater clarity. Similarly, right now it’s important to focus on understanding rather than making assumptions about environmental factors like seasonality.

But the biggest question on everyone’s lips is, “When?” When will we see therapeutic progress against Covid-19? And when will life get “back to normal”? There are lots of models out there on the internet; which of those models are right? The simple answer is “none of them.” That’s right—it’s almost certain that every model you’ve seen is wrong in at least one detail, if not all of them. But modeling is meant to be a tool for deeper thinking, a way to run mental (and computational) experiments before—and while—taking action. As George E. P. Box famously wrote in 1976, “All models are wrong, but some are useful.”

Here, we’re seeking useful insights, as opposed to exact predictions, which is why we’re pulling back from quantitative details to get at the mindsets that will support agency and hope. To that end, I’ve been putting together timelines that I believe will yield useful expectations for the next year or two—and asking how optimistic I need to be in order to believe a particular timeline.

For a moderately optimistic scenario to be relevant, breakthroughs in science and technology come at paces expected based on previous efforts and assumptions that turn out to be basically correct; accessibility of those breakthroughs increases at a reasonable pace; regulation achieves its desired effects, without major surprises; and compliance with regulations is reasonably high.

In contrast, if I’m being highly optimistic, breakthroughs in science and technology and their accessibility come more quickly than they ever have before; regulation is evidence-based and successful in the first try or two; and compliance with those regulations is high and uniform. If I’m feeling not-so-optimistic, then I anticipate serious setbacks to breakthroughs and accessibility (with the overturning of many important assumptions), repeated failure of regulations to achieve their desired outcomes, and low compliance with those regulations.

The following scenarios outline the things that need to happen in the fight against Covid-19, when I expect to see them, and how confident I feel in those expectations. They focus on North America and Europe because there are data missing about China’s 2019 outbreak and other regions are still early in their outbreaks. Perhaps the most important thing to keep in mind throughout: We know more today than we did yesterday, but we still have much to learn. New knowledge derived from greater study and debate will almost certainly inspire ongoing course corrections.

As you dive into the scenarios below, practice these three mindset shifts. First, defeating Covid-19 will be a marathon, not a sprint. We shouldn’t expect life to look like 2019 for the next year or two—if ever. As Ed Yong wrote recently in The Atlantic, “There won’t be an obvious moment when everything is under control and regular life can safely resume.” Second, remember that you have important things to do for at least a year. And third, we are all in this together. There is no “us” and “them.” We must all be alert, responsive, generous, and strong throughout 2020 and 2021—and willing to throw away our assumptions when scientific evidence invalidates them.

The Middle Way: Moderate Optimism
Let’s start with the case in which I have the most confidence: moderate optimism.

This timeline considers milestones through late 2021, the earliest that I believe vaccines will become available. The “normal” timeline for developing a vaccine for diseases like seasonal flu is 18 months, which leads to my projection that we could potentially have vaccines as soon as 18 months from the first quarter of 2020. While Melinda Gates agrees with that projection, others (including AI) believe that 3 to 5 years is far more realistic, based on past vaccine development and the need to test safety and efficacy in humans. However, repurposing existing vaccines against other diseases—or piggybacking off clever synthetic platforms—could lead to vaccines being available sooner. I tried to balance these considerations for this moderately optimistic scenario. Either way, deploying vaccines at the end of 2021 is probably much later than you may have been led to believe by the hype engine. Again, if you take away only one message from this article, remember that the fight against Covid-19 is a marathon, not a sprint.

Here, I’ve visualized a moderately optimistic scenario as a baseline. Think of these timelines as living guides, as opposed to exact predictions. There are still many unknowns. More or less optimistic views (see below) and new information could shift these timelines forward or back and change the details of the strategies.
Based on current data, I expect that the first wave of Covid-19 cases (where we are now) will continue to subside in many areas, leading governments to ease restrictions in an effort to get people back to work. We’re already seeing movement in that direction, with a variety of benchmarks and changes at state and country levels around the world. But depending on the details of the changes, easing restrictions will probably cause a second wave of sickness (see Germany and Singapore), which should lead governments to reimpose at least some restrictions.

In tandem, therapeutic efforts will be transitioning from emergency treatments to treatments that have been approved based on safety and efficacy data in clinical trials. In a moderately optimistic scenario, assuming clinical trials currently underway yield at least a few positive results, this shift to mostly approved therapies could happen as early as the third or fourth quarter of this year and continue from there. One approval that should come rather quickly is for plasma therapies, in which the blood from people who have recovered from Covid-19 is used as a source of antibodies for people who are currently sick.

Companies around the world are working on both viral and antibody testing, focusing on speed, accuracy, reliability, and wide accessibility. While these tests are currently being run in hospitals and research laboratories, at-home testing is a critical component of the mass testing we’ll need to keep viral spread in check. These are needed to minimize the impact of asymptomatic cases, test the assumption that infection yields resistance to subsequent infection (and whether it lasts), and construct potential immunity passports if this assumption holds. Testing is also needed for contact tracing efforts to prevent further spread and get people back to public life. Finally, it’s crucial to our fundamental understanding of the biology of SARS-CoV-2 and Covid-19.

We need tests that are very reliable, both in the clinic and at home. So, don’t go buying any at-home test kits just yet, even if you find them online. Wait for reliable test kits and deeper understanding of how a test result translates to everyday realities. If we’re moderately optimistic, in-clinic testing will rapidly expand this quarter and/or next, with the possibility of broadly available, high-quality at-home sampling (and perhaps even analysis) thereafter.

Note that testing is not likely to be a “one-and-done” endeavor, as a person’s infection and immunity status change over time. Expect to be testing yourself—and your family—often as we move later into 2020.

Testing data are also going to inform distancing requirements at the country and local levels. In this scenario, restrictions—at some level of stringency—could persist at least through the end of 2020, as most countries are way behind the curve on testing (Iceland is an informative exception). Governments will likely continue to ask citizens to work from home if at all possible; to wear masks or face coverings in public; to employ heightened hygiene and social distancing in workplaces; and to restrict travel and social gatherings. So while it’s likely we’ll be eating in local restaurants again in 2020 in this scenario, at least for a little while, it’s not likely we’ll be heading to big concerts any time soon.

The Extremes: High and Low Optimism
How would high and low levels of optimism change our moderately optimistic timeline? The milestones are the same, but the time required to achieve them is shorter or longer, respectively. Quantifying these shifts is less important than acknowledging and incorporating a range of possibilities into our view. It pays to pay attention to our bias. Here are a few examples of reasonable possibilities that could shift the moderately optimistic timeline.

When vaccines become available
Vaccine repurposing could shorten the time for vaccines to become available; today, many vaccine candidates are in various stages of testing. On the other hand, difficulties in manufacture and distribution, or faster-than-expected mutation of SARS-CoV-2, could slow vaccine development. Given what we know now, I am not strongly concerned about either of these possibilities—drug companies are rapidly expanding their capabilities, and viral mutation isn’t an urgent concern at this time based on sequencing data—but they could happen.

At first, governments will likely supply vaccines to essential workers such as healthcare workers, but it is essential that vaccines become widely available around the world as quickly and as safely as possible. Overall, I suggest a dose of skepticism when reading highly optimistic claims about a vaccine (or multiple vaccines) being available in 2020. Remember, a vaccine is a knockout punch, not a first line of defense for an outbreak.

When testing hits its stride
While I am confident that testing is a critical component of our response to Covid-19, reliability is incredibly important to testing for SARS-CoV-2 and for immunity to the disease, particularly at home. For an individual, a false negative (being told you don’t have antibodies when you really do) could be just as bad as a false positive (being told you do have antibodies when you really don’t). Those errors are compounded when governments are trying to make evidence-based policies for social and physical distancing.

If you’re highly optimistic, high-quality testing will ramp up quickly as companies and scientists innovate rapidly by cleverly combining multiple test modalities, digital signals, and cutting-edge tech like CRISPR. Pop-up testing labs could also take some pressure off hospitals and clinics.

If things don’t go well, reliability issues could hinder testing, manufacturing bottlenecks could limit availability, and both could hamstring efforts to control spread and ease restrictions. And if it turns out that immunity to Covid-19 isn’t working the way we assumed, then we must revisit our assumptions about our path(s) back to public life, as well as our vaccine-development strategies.

How quickly safe and effective treatments appear
Drug development is known to be long, costly, and fraught with failure. It’s not uncommon to see hope in a drug spike early only to be dashed later on down the road. With that in mind, the number of treatments currently under investigation is astonishing, as is the speed through which they’re proceeding through testing. Breakthroughs in a therapeutic area—for example in treating the seriously ill or in reducing viral spread after an infection takes hold—could motivate changes in the focus of distancing regulations.

While speed will save lives, we cannot overlook the importance of knowing a treatment’s efficacy (does it work against Covid-19?) and safety (does it make you sick in a different, or worse, way?). Repurposing drugs that have already been tested for other diseases is speeding innovation here, as is artificial intelligence.

Remarkable collaborations among governments and companies, large and small, are driving innovation in therapeutics and devices such as ventilators for treating the sick.

Whether government policies are effective and responsive
Those of us who have experienced lockdown are eager for it to be over. Businesses, economists, and governments are also eager to relieve the terrible pressure that is being exerted on the global economy. However, lifting restrictions will almost certainly lead to a resurgence in sickness.

Here, the future is hard to model because there are many, many factors at play, and at play differently in different places—including the extent to which individuals actually comply with regulations.

Reliable testing—both in the clinic and at home—is crucial to designing and implementing restrictions, monitoring their effectiveness, and updating them; delays in reliable testing could seriously hamper this design cycle. Lack of trust in governments and/or companies could also suppress uptake. That said, systems are already in place for contact tracing in East Asia. Other governments could learn important lessons, but must also earn—and keep—their citizens’ trust.

Expect to see restrictions descend and then lift in response to changes in the number of Covid-19 cases and in the effectiveness of our prevention strategies. Also expect country-specific and perhaps even area-specific responses that differ from each other. The benefit of this approach? Governments around the world are running perhaps hundreds of real-time experiments and design cycles in balancing health and the economy, and we can learn from the results.

A Way Out
As Jeremy Farrar, head of the Wellcome Trust, told Science magazine, “Science is the exit strategy.” Some of our greatest technological assistance is coming from artificial intelligence, digital tools for collaboration, and advances in biotechnology.

Our exit strategy also needs to include empathy and future visioning—because in the midst of this crisis, we are breaking ground for a new, post-Covid future.

What do we want that future to look like? How will the hard choices we make now about data ethics impact the future of surveillance? Will we continue to embrace inclusiveness and mass collaboration? Perhaps most importantly, will we lay the foundation for successfully confronting future challenges? Whether we’re thinking about the next pandemic (and there will be others) or the cascade of catastrophes that climate change is bringing ever closer—it’s important to remember that we all have the power to become agents of that change.

Special thanks to Ola Kowalewski and Jason Dorrier for significant conversations.

Image Credit: Drew Beamer / Unsplash Continue reading →

Posted in Human Robots

#436530 How Smart Roads Will Make Driving ...

Posted on January 30, 2020 by Android

Roads criss-cross the landscape, but while they provide vital transport links, in many ways they represent a huge amount of wasted space. Advances in “smart road” technology could change that, creating roads that can harvest energy from cars, detect speeding, automatically weigh vehicles, and even communicate with smart cars.

“Smart city” projects are popping up in countries across the world thanks to advances in wireless communication, cloud computing, data analytics, remote sensing, and artificial intelligence. Transportation is a crucial element of most of these plans, but while much of the focus is on public transport solutions, smart roads are increasingly being seen as a crucial feature of these programs.

New technology is making it possible to tackle a host of issues including traffic congestion, accidents, and pollution, say the authors of a paper in the journal Proceedings of the Royal Society A. And they’ve outlined ten of the most promising advances under development or in planning stages that could feature on tomorrow’s roads.

Energy harvesting

A variety of energy harvesting technologies integrated into roads have been proposed as ways to power street lights and traffic signals or provide a boost to the grid. Photovoltaic panels could be built into the road surface to capture sunlight, or piezoelectric materials installed beneath the asphalt could generate current when deformed by vehicles passing overhead.

Musical roads

Countries like Japan, Denmark, the Netherlands, Taiwan, and South Korea have built roads that play music as cars pass by. By varying the spacing of rumble strips, it’s possible to produce a series of different notes as vehicles drive over them. The aim is generally to warn of hazards or help drivers keep to the speed limit.

Automatic weighing

Weight-in-motion technology that measures vehicles’ loads as they drive slowly through a designated lane has been around since the 1970s, but more recently high speed weight-in-motion tech has made it possible to measure vehicles as they travel at regular highway speeds. The latest advance has been integration with automatic licence plate reading and wireless communication to allow continuous remote monitoring both to enforce weight restrictions and monitor wear on roads.

Vehicle charging

The growing popularity of electric vehicles has spurred the development of technology to charge cars and buses as they drive. The most promising of these approaches is magnetic induction, which involves burying cables beneath the road to generate electromagnetic fields that a receiver device in the car then transforms into electrical power to charge batteries.

Smart traffic signs

Traffic signs aren’t always as visible as they should be, and it can often be hard to remember what all of them mean. So there are now proposals for “smart signs” that wirelessly beam a sign’s content to oncoming cars fitted with receivers, which can then alert the driver verbally or on the car’s display. The approach isn’t affected by poor weather and lighting, can be reprogrammed easily, and could do away with the need for complex sign recognition technology in future self-driving cars.

Traffic violation detection and notification

Sensors and cameras can be combined with these same smart signs to detect and automatically notify drivers of traffic violations. The automatic transmission of traffic signals means drivers won’t be able to deny they’ve seen the warnings or been notified of any fines, as a record will be stored on their car’s black box.

Talking cars

Car-to-car communication technology and V2X, which lets cars share information with any other connected device, are becoming increasingly common. Inter-car communication can be used to propagate accidents or traffic jam alerts to prevent congestion, while letting vehicles communicate with infrastructure can help signals dynamically manage timers to keep traffic flowing or automatically collect tolls.

Smart intersections

Combing sensors and cameras with object recognition systems that can detect vehicles and other road users can help increase safety and efficiency at intersections. It can be used to extend green lights for slower road users like pedestrians and cyclists, sense jaywalkers, give priority to emergency vehicles, and dynamically adjust light timers to optimize traffic flow. Information can even be broadcast to oncoming vehicles to highlight blind spots and potential hazards.

Automatic crash detection

There’s a “golden hour” after an accident in which the chance of saving lives is greatly increased. Vehicle communication technology can ensure that notification of a crash reaches the emergency services rapidly, and can also provide vital information about the number and type of vehicles involved, which can help emergency response planning. It can also be used to alert other drivers to slow down or stop to prevent further accidents.

Smart street lights

Street lights are increasingly being embedded with sensors, wireless connectivity, and micro-controllers to enable a variety of smart functions. These include motion activation to save energy, providing wireless access points, air quality monitoring, or parking and litter monitoring. This can also be used to send automatic maintenance requests if a light is faulty, and can even allow neighboring lights to be automatically brightened to compensate.

Image Credit: Image by David Mark from Pixabay Continue reading →

Posted in Human Robots

#436258 For Centuries, People Dreamed of a ...

Posted on December 2, 2019 by Android

This is part six of a six-part series on the history of natural language processing.

In February of this year, OpenAI, one of the foremost artificial intelligence labs in the world, announced that a team of researchers had built a powerful new text generator called the Generative Pre-Trained Transformer 2, or GPT-2 for short. The researchers used a reinforcement learning algorithm to train their system on a broad set of natural language processing (NLP) capabilities, including reading comprehension, machine translation, and the ability to generate long strings of coherent text.

But as is often the case with NLP technology, the tool held both great promise and great peril. Researchers and policy makers at the lab were concerned that their system, if widely released, could be exploited by bad actors and misappropriated for “malicious purposes.”

The people of OpenAI, which defines its mission as “discovering and enacting the path to safe artificial general intelligence,” were concerned that GPT-2 could be used to flood the Internet with fake text, thereby degrading an already fragile information ecosystem. For this reason, OpenAI decided that it would not release the full version of GPT-2 to the public or other researchers.

GPT-2 is an example of a technique in NLP called language modeling, whereby the computational system internalizes a statistical blueprint of a text so it’s able to mimic it. Just like the predictive text on your phone—which selects words based on words you’ve used before—GPT-2 can look at a string of text and then predict what the next word is likely to be based on the probabilities inherent in that text.

GPT-2 can be seen as a descendant of the statistical language modeling that the Russian mathematician A. A. Markov developed in the early 20th century (covered in part three of this series).

GPT-2 used cutting-edge machine learning algorithms to do linguistic analysis with over 1.5 million parameters.

What’s different with GPT-2, though, is the scale of the textual data modeled by the system. Whereas Markov analyzed a string of 20,000 letters to create a rudimentary model that could predict the likelihood of the next letter of a text being a consonant or a vowel, GPT-2 used 8 million articles scraped from Reddit to predict what the next word might be within that entire dataset.

And whereas Markov manually trained his model by counting only two parameters—vowels and consonants—GPT-2 used cutting-edge machine learning algorithms to do linguistic analysis with over 1.5 million parameters, burning through huge amounts of computational power in the process.

The results were impressive. In their blog post, OpenAI reported that GPT-2 could generate synthetic text in response to prompts, mimicking whatever style of text it was shown. If you prompt the system with a line of William Blake’s poetry, it can generate a line back in the Romantic poet’s style. If you prompt the system with a cake recipe, you get a newly invented recipe in response.

Perhaps the most compelling feature of GPT-2 is that it can answer questions accurately. For example, when OpenAI researchers asked the system, “Who wrote the book The Origin of Species?”—it responded: “Charles Darwin.” While only able to respond accurately some of the time, the feature does seem to be a limited realization of Gottfried Leibniz’s dream of a language-generating machine that could answer any and all human questions (described in part two of this series).

After observing the power of the new system in practice, OpenAI elected not to release the fully trained model. In the lead up to its release in February, there had been heightened awareness about “deepfakes”—synthetic images and videos, generated via machine learning techniques, in which people do and say things they haven’t really done and said. Researchers at OpenAI worried that GPT-2 could be used to essentially create deepfake text, making it harder for people to trust textual information online.

Responses to this decision varied. On one hand, OpenAI’s caution prompted an overblown reaction in the media, with articles about the “dangerous” technology feeding into the Frankenstein narrative that often surrounds developments in AI.

Others took issue with OpenAI’s self-promotion, with some even suggesting that OpenAI purposefully exaggerated GPT-2s power in order to create hype—while contravening a norm in the AI research community, where labs routinely share data, code, and pre-trained models. As machine learning researcher Zachary Lipton tweeted, “Perhaps what's *most remarkable* about the @OpenAI controversy is how *unremarkable* the technology is. Despite their outsize attention & budget, the research itself is perfectly ordinary—right in the main branch of deep learning NLP research.”

OpenAI stood by its decision to release only a limited version of GPT-2, but has since released larger models for other researchers and the public to experiment with. As yet, there has been no reported case of a widely distributed fake news article generated by the system. But there have been a number of interesting spin-off projects, including GPT-2 poetry and a webpage where you can prompt the system with questions yourself.

Mimicking humans on Reddit, the bots have long conversations about a variety of topics, including conspiracy theories and
Star Wars movies.

There’s even a Reddit group populated entirely with text produced by GPT-2-powered bots. Mimicking humans on Reddit, the bots have long conversations about a variety of topics, including conspiracy theories and Star Wars movies.

This bot-powered conversation may signify the new condition of life online, where language is increasingly created by a combination of human and non-human agents, and where maintaining the distinction between human and non-human, despite our best efforts, is increasingly difficult.

The idea of using rules, mechanisms, and algorithms to generate language has inspired people in many different cultures throughout history. But it’s in the online world that this powerful form of wordcraft may really find its natural milieu—in an environment where the identity of speakers becomes more ambiguous, and perhaps, less relevant. It remains to be seen what the consequences will be for language, communication, and our sense of human identity, which is so bound up with our ability to speak in natural language.

This is the sixth installment of a six-part series on the history of natural language processing. Last week’s post explained how an innocent Microsoft chatbot turned instantly racist on Twitter.

You can also check out our prior series on the untold history of AI. Continue reading →

Posted in Human Robots

#435687 Humanoid Robots Teach Coping Skills to ...

Posted on September 16, 2019 by Android

Photo: Rob Felt

IEEE Senior Member Ayanna Howard with one of the interactive androids that help children with autism improve their social and emotional engagement.

THE INSTITUTEChildren with autism spectrum disorder can have a difficult time expressing their emotions and can be highly sensitive to sound, sight, and touch. That sometimes restricts their participation in everyday activities, leaving them socially isolated. Occupational therapists can help them cope better, but the time they’re able to spend is limited and the sessions tend to be expensive.

Roboticist Ayanna Howard, an IEEE senior member, has been using interactive androids to guide children with autism on ways to socially and emotionally engage with others—as a supplement to therapy. Howard is chair of the School of Interactive Computing and director of the Human-Automation Systems Lab at Georgia Tech. She helped found Zyrobotics, a Georgia Tech VentureLab startup that is working on AI and robotics technologies to engage children with special needs. Last year Forbes named Howard, Zyrobotics’ chief technology officer, one of the Top 50 U.S. Women in Tech.

In a recent study, Howard and other researchers explored how robots might help children navigate sensory experiences. The experiment involved 18 participants between the ages of 4 and 12; five had autism, and the rest were meeting typical developmental milestones. Two humanoid robots were programmed to express boredom, excitement, nervousness, and 17 other emotional states. As children explored stations set up for hearing, seeing, smelling, tasting, and touching, the robots modeled what the socially acceptable responses should be.

“If a child’s expression is one of happiness or joy, the robot will have a corresponding response of encouragement,” Howard says. “If there are aspects of frustration or sadness, the robot will provide input to try again.” The study suggested that many children with autism exhibit stronger levels of engagement when the robots interact with them at such sensory stations.

It is one of many robotics projects Howard has tackled. She has designed robots for researching glaciers, and she is working on assistive robots for the home, as well as an exoskeleton that can help children who have motor disabilities.

Howard spoke about her work during the Ethics in AI: Impacts of (Anti?) Social Robotics panel session held in May at the IEEE Vision, Innovation, and Challenges Summit in San Diego. You can watch the session on IEEE.tv.

The next IEEE Vision, Innovation, and Challenges Summit and Honors Ceremony will be held on 15 May 2020 at the JW Marriott Parq Vancouver hotel, in Vancouver.

In this interview with The Institute, Howard talks about how she got involved with assistive technologies, the need for a more diverse workforce, and ways IEEE has benefited her career.

FOCUS ON ACCESSIBILITY
Howard was inspired to work on technology that can improve accessibility in 2008 while teaching high school students at a summer camp devoted to science, technology, engineering, and math.

“A young lady with a visual impairment attended camp. The robot programming tools being used at the camp weren’t accessible to her,” Howard says. “As an engineer, I want to fix problems when I see them, so we ended up designing tools to enable access to programming tools that could be used in STEM education.

“That was my starting motivation, and this theme of accessibility has expanded to become a main focus of my research. One of the things about this world of accessibility is that when you start interacting with kids and parents, you discover another world out there of assistive technologies and how robotics can be used for good in education as well as therapy.”

DIVERSITY OF THOUGHT
The Institute asked Howard why it’s important to have a more diverse STEM workforce and what could be done to increase the number of women and others from underrepresented groups.

“The makeup of the current engineering workforce isn’t necessarily representative of the world, which is composed of different races, cultures, ages, disabilities, and socio-economic backgrounds,” Howard says. “We’re creating products used by people around the globe, so we have to ensure they’re being designed for a diverse population. As IEEE members, we also need to engage with people who aren’t engineers, and we don’t do that enough.”

Educational institutions are doing a better job of increasing diversity in areas such as gender, she says, adding that more work is needed because the enrollment numbers still aren’t representative of the population and the gains don’t necessarily carry through after graduation.

“There has been an increase in the number of underrepresented minorities and females going into engineering and computer science,” she says, “but data has shown that their numbers are not sustained in the workforce.”

ROLE MODEL
Because there are more underrepresented groups on today’s college campuses that can form a community, the lack of engineering role models—although a concern on campuses—is more extreme for preuniversity students, Howard says.

“Depending on where you go to school, you may not know what an engineer does or even consider engineering as an option,” she says, “so there’s still a big disconnect there.”

Howard has been involved for many years in math- and science-mentoring programs for at-risk high school girls. She tells them to find what they’re passionate about and combine it with math and science to create something. She also advises them not to let anyone tell them that they can’t.

Howard’s father is an engineer. She says he never encouraged or discouraged her to become one, but when she broke something, he would show her how to fix it and talk her through the process. Along the way, he taught her a logical way of thinking she says all engineers have.

“When I would try to explain something, he would quiz me and tell me to ‘think more logically,’” she says.

Howard earned a bachelor’s degree in engineering from Brown University, in Providence, R.I., then she received both a master’s and doctorate degree in electrical engineering from the University of Southern California. Before joining the faculty of Georgia Tech in 2005, she worked at NASA’s Jet Propulsion Laboratory at the California Institute of Technology for more than a decade as a senior robotics researcher and deputy manager in the Office of the Chief Scientist.

ACTIVE VOLUNTEER
Howard’s father was also an IEEE member, but that’s not why she joined the organization. She says she signed up when she was a student because, “that was something that you just did. Plus, my student membership fee was subsidized.”

She kept the membership as a grad student because of the discounted rates members receive on conferences.

Those conferences have had an impact on her career. “They allow you to understand what the state of the art is,” she says. “Back then you received a printed conference proceeding and reading through it was brutal, but by attending it in person, you got a 15-minute snippet about the research.”

Howard is an active volunteer with the IEEE Robotics and Automation and the IEEE Systems, Man, and Cybernetics societies, holding many positions and serving on several committees. She is also featured in the IEEE Impact Creators campaign. These members were selected because they inspire others to innovate for a better tomorrow.

“I value IEEE for its community,” she says. “One of the nice things about IEEE is that it’s international.” Continue reading →

Posted in Human Robots